Evolution and Treatments of Chronic Inflammatory Systemic Diseases

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Besancon

About this trial

Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease \[MC\] and ulcerative colitis \[RCH\]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis \[RA\] and spondyloarthritis \[SpA\] including psoriatic arthritis \[PsA\]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital

Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or

Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or

Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon

Disqualifiers

Opposition of the patient

Patients in emergency situation, persons deprived of their liberty, protected minors or adults.

Trial population

Patients with Inflammatory Bowel Disease, Chronic Inflammatory Skin Diseases or Chronic inflammatory rheumatic disease

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

3,000 Participants
are grouped into 3 trial groups
Group A: Inflammatory bowel disease
Group B: Chronic inflammatory rheumatic disease
Group C: Chronic inflammatory skin diseases

Trial outcomes

Primary outcomes

1

Diagnosis of a second inflammatory disease

Time frame
through study completion (up to 10 years)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.